Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Select Medical Holdings / Technical Analysis

<ul>
<li>We are starting to see some positive signals that suggest the lows for this bear market may have already been established, or that additional downside is limited from here.</li>
<li>We need to see downtrend reversals (get above 4030-4040 on SPX, $189 on IWM, and $115 on IWC) and for the NDX(QQQ) to break above $315, to get more constructive.</li>
<li>Positive signals include, among other things: the Financial Sector (XLF) and Broker-Dealers/Exchanges ETF (IAI) are reversing topside their 4-5-month downtrends.</li>
</ul>


We are starting to see some positive signals that suggest the lows for this bear market may have already been established, or that additional downside is limited from here.
We need to see downtrend reversals (get above 4030-4040 on SPX, $189 on IWM, and $115 on IWC) and for the NDX(QQQ) to break above $315, to get more constructive.
Positive signals include, among other things: the Financial Sector (XLF) and Broker-Dealers/Exchanges ETF (IAI) are reversing topside their 4-5-month downtrends.


Downgrading Utilities & Staples to Market Weight; Buy Ideas in Health Care & Trucking

Quality-first, Business-perspective Strategy, Urbem (HK) Limited

Steven Chen

Quality-first, Business-perspective Strategy

Equity Bottom-Up

<ul data-v-2d66ea9f="">
<li data-v-2d66ea9f="">We like to regard managers of our (partially) owned companies as trusted partners, and therefore, look for owner-oriented stewards that treat shareholders fairly;</li>
<li data-v-2d66ea9f="">We present some easy-to-grasp gimmicks that can be leveraged to gauge this factor.</li>
</ul>


We like to regard managers of our (partially) owned companies as trusted partners, and therefore, look for owner-oriented stewards that treat shareholders fairly;
We present some easy-to-grasp gimmicks that can be leveraged to gauge this factor.


Some Easy-To-Grasp Gimmicks to Gauge Management Compensation

Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&amp;P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. In today’s report we highlight attractive stocks from a relative strength perspective across Sectors.

Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&amp;P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. In today’s report we highlight attractive stocks from a relative strength perspective across Sectors.

U.S. Equity Strategy: Bulls Still In Driver’s Seat, But For How Long?

Now that the initial/primary low has been established and with the S&amp;P 500 roughly 20% off the lows, we believe it is time to map out potential areas where this rally could run into resistance. After this type of major waterfall decline there is often a test of the initial low - and there is often an undercut of the initial low. Barring approval of a first-line therapy for COVID-19 (chloroquine/hydroxychloroquine?) we are of the belief that a test of this initial low (likely 2-12 weeks out) and potentially an undercut of roughly 10% are likely.

Now that the initial/primary low has been established and with the S&amp;P 500 roughly 20% off the lows, we believe it is time to map out potential areas where this rally could run into resistance. After this type of major waterfall decline there is often a test of the initial low - and there is often an undercut of the initial low. Barring approval of a first-line therapy for COVID-19 (chloroquine/hydroxychloroquine?) we are of the belief that a test of this initial low (likely 2-12 weeks out) and potentially an undercut of roughly 10% are likely.

We remain skeptical of the market's upside potential, as we are not sure if anything actually changed in Fed policy, or as a result of the U.S./China trade ceasefire, which has seemingly raised more questions than answers. With that said, 2,817 remains the key resistance level in focus on the S&amp;P 500. In today’s report we highlight attractive opportunities within Airlines, and Home Health Care Services.

We remain skeptical of the market's upside potential, as we are not sure if anything actually changed in Fed policy, or as a result of the U.S./China trade ceasefire, which has seemingly raised more questions than answers. With that said, 2,817 remains the key resistance level in focus on the S&amp;P 500. In today’s report we highlight attractive opportunities within Airlines, and Home Health Care Services.

U.S. Equity Strategy: S&P 500 Fails at Resistance

United States

Chemed Corporation operates in the healthcare field through its subsidiary Vitas Healthcare Corporation.  The Company also maintains a presence in the residential and commercial repair-and-maintenance-service industry under the names Roto-Rooter and Service America Network Inc.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chemed Corp (CHE US)

Downgrading Utilities & Staples to Market Weight; Buy Ideas in Health Care & Trucking

Positive developments are popping up, such as bullish reversals of 4-5-month downtrends for Financials $XLF and Broker-Dealers/Exchanges $IAI ....

Vermilion Research

Some Easy-To-Grasp Gimmicks to Gauge Management Compensation

Additionally, here are two US-listed mid-cap companies we have been following to illustrate both sides of the management pay matter.

Steven Chen

U.S. Equity Strategy: Bulls Still In Driver’s Seat, But For How Long?

Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the...

Vermilion Research

U.S. Equities: Test Of The Lows Coming?

Now that the initial/primary low has been established and with the S&P 500 roughly 20% off the lows, we believe it is time to map out potential...

Vermilion Research

U.S. Equity Strategy: S&P 500 Fails at Resistance

We remain skeptical of the market's upside potential, as we are not sure if anything actually changed in Fed policy, or as a result of the...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)